カテゴリ： GlobalData, アメリカ, 企業調査

Adamas Pharmaceuticals Inc (ADMS)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Adamas Pharmaceuticals Inc (ADMS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9793
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：73
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Adamas Pharmaceuticals Inc (Adamas Pharmaceuticals) is a pharmaceutical company that develops and commercializes therapeutics for chronic disorders of the central nervous system. The company’s Gocovri, formerly ADS-5102, is an amantadine extended-release (XR) formulation for the treatment for dyskinesia in patients with Parkinson’s disease. Gocovri is a high-dose, once-daily indication designed to deliver high level of amantadine in the morning and throughout the day when dyskinesia occurs. Its pipeline includes ADS-5102 for the treatment of wearing OFF, and delaying motor complications in Parkinson’s disease; Huntington’s chorea; tardive dyskinesia; non-motor disorders, including depression, and anti-psychotic induced weight gain; and Tourette syndrome; and various others indications; and ADS-4101 in Phase 3 for the treatment of partial onset seizures in patients with epilepsy. The company also offers namzaric and namenda XR for the treatment of moderate to severe Alzheimer’s disease. Adamas Pharmaceuticals is headquartered in Emeryville, California, the US.

Adamas Pharmaceuticals Inc (ADMS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Adamas Pharma Raises USD143.2 Million in Public Offering of Shares 11
Adamas Pharma Raises USD9.7 Million in Private Placement of Shares 13
Adamas Pharma Plans to Raise up to USD200 Million in Public Offering of Shares 14
Adamas Pharma Raises USD66 Million in Public Offering of Shares 15
Adamas Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 17
Adamas Pharma Completes IPO For US$48 Million 18
Debt Offering 20
Adamas Pharma Raises USD35 Million in Private Placement of 11% Royalty-Backed Note Due 2026 20
Adamas Pharmaceuticals Inc – Key Competitors 21
Adamas Pharmaceuticals Inc – Key Employees 22
Adamas Pharmaceuticals Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Nov 02, 2018: Adamas reports third quarter 2018 financial results 24
Aug 02, 2018: Adamas announces second quarter 2018 financial results 26
May 03, 2018: Adamas Reports First Quarter 2018 Financial Results 27
Feb 22, 2018: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017 28
Nov 02, 2017: Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results 30
Aug 08, 2017: Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results 32
May 09, 2017: Adamas Reports Recent Achievements and First Quarter 2017 Financial Results 34
Feb 28, 2017: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2016 35
Corporate Communications 37
Jun 28, 2017: Adamas Appoints New Chief Financial Officer 37
Apr 27, 2017: Adamas Pharmaceuticals appoints new COO 38
Product News 39
10/11/2017: Adamas Appoints Mardi C. Dier to its Board of Directors 39
09/13/2017: Adamas to Host Investor and Analyst Meeting on September 18, 2017 40
08/24/2017: Adamas Announces FDA Approval of GOCOVRI as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients 41
05/24/2018: Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI in Clinical Pharmacokinetics 42
04/27/2017: Adamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102 43
04/12/2018: Adamas Announces Data Presentations on GOCOVRI at The American Academy Of Neurology Annual Meeting 44
01/08/2018: Adamas Announces U.S. Commercial Launch of GOCOVRI the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinsons Disease Patients 46
01/08/2017: Adamas Pharma Outlines Key Business Priorities for 2017, Provides Update on ADS-5102 47
01/08/2017: Adamas Pharmaceuticals Outlines Key Business Priorities for 2017, Provides Update on ADS-4101 48
Product Approvals 49
Oct 25, 2017: FDA Recognizes Orphan Drug Exclusivity for Adamas’ GOCOVRI 49
Jan 06, 2017: Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson’s Disease 50
Clinical Trials 51
Jun 22, 2018: Adamas Presents New Data Analysis Demonstrating that GOCOVRI Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day 51
Apr 19, 2018: Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI in Parkinson’s Disease Patients with Dyskinesia 52
Apr 12, 2018: Adamas Announces Data Presentations on ADS-4101 at The American Academy Of Neurology Annual Meeting 54
Apr 03, 2018: Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment 55
Mar 15, 2018: Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI in Parkinson Disease Patients with Dyskinesia 56
Feb 08, 2018: Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice 57
Feb 01, 2018: Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal 58
Sep 07, 2017: Adamas Announces Topline Phase 1b Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy 59
Jun 12, 2017: Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology 60
Jun 08, 2017: Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks 62
May 22, 2017: Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy 64
Apr 24, 2017: Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson’s Disease 66
Apr 18, 2017: Adamas Announces Oral and Poster Presentations of ADS-5102 Pooled Phase 3 Data at the 69th American Academy of Neurology Annual Meeting 68
Mar 28, 2017: Adamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual Meeting 69
Feb 28, 2017: Adamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinson’s Disease and Movement Disorders Congress 70
Feb 17, 2017: Adamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis at ACTRIMS Forum 2017 71
Jan 03, 2017: Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73

List of Tables
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adamas Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adamas Pharma Raises USD143.2 Million in Public Offering of Shares 11
Adamas Pharma Raises USD9.7 Million in Private Placement of Shares 13
Adamas Pharma Plans to Raise up to USD200 Million in Public Offering of Shares 14
Adamas Pharma Raises USD66 Million in Public Offering of Shares 15
Adamas Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 17
Adamas Pharma Completes IPO For US$48 Million 18
Adamas Pharma Raises USD35 Million in Private Placement of 11% Royalty-Backed Note Due 2026 20
Adamas Pharmaceuticals Inc, Key Competitors 21
Adamas Pharmaceuticals Inc, Key Employees 22

List of Figures
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Adamas Pharmaceuticals Inc (ADMS)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Aradigm Corp (ARDM)：医療機器：M&Aディール及び事業提携情報
    Summary Aradigm Corp (Aradigm) is a specialty pharmaceutical company that develops and commercializes inhalation drugs for the prevention and treatment of severe respiratory diseases. The company's product pipeline includes Pulmaquin (ARD-3150) and Lipoquin (ARD-3100) for the treatment of non-cystic …
  • Kulim (Malaysia) Bhd：企業の戦略的SWOT分析
    Kulim (Malaysia) Bhd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Centogene AG-医療機器分野：企業M&A・提携分析
    Summary Centogene AG (Centogene) is a provider of genetic testing services. The company offers genetic testing for rare hereditary disorders. It offers whole genome sequencing, whole exome sequencing, biomarker and biochemical testing; prenatal testing, DNA extraction and cell culture services. Cent …
  • Royal DSM NV (DSM)-製薬・医療分野：企業M&A・提携分析
    Summary Royal DSM NV (DSM) is a life sciences and materials sciences company, which focuses on health, nutrition and materials sectors. The company offers a wide range of products such as anti-invectives, polyesters, vitamins and other ingredients, performance materials to diverse end markets. It pr …
  • Fiserv, Inc.：企業の戦略・SWOT・財務情報
    Fiserv, Inc. - Strategy, SWOT and Corporate Finance Report Summary Fiserv, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Affinivax Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Affinivax Inc (Affinivax) is a biotechnology company that develops vaccines for infectious diseases. The company uses Multiple Antigen Presenting System technology to enable affinity binding of protective polysaccharides and proteins in a single vaccine. It develops vaccine programs for stre …
  • Saniona AB (SANION)：製薬・医療：M&Aディール及び事業提携情報
    Summary Saniona AB (Saniona), formerly Aniona is a research and development company that develops drugs for central nervous system diseases, autoimmune diseases, metabolic diseases and pain management. The company’s pipeline products include tesofensine, a triple monoamine reuptake inhibitor, which …
  • Mitsubishi Heavy Industries, Ltd.：企業の戦略・SWOT・財務分析
    Mitsubishi Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Central Garden & Pet Company：企業の戦略・SWOT・財務情報
    Central Garden & Pet Company - Strategy, SWOT and Corporate Finance Report Summary Central Garden & Pet Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Enel Generacion Chile SA：発電所・企業SWOT分析
    Enel Generacion Chile SA - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Pactiv Evergreen Inc (PTVE)：企業の財務・戦略的SWOT分析
    Pactiv Evergreen Inc (PTVE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Moog Inc (MOG.A)：企業の財務・戦略的SWOT分析
    Moog Inc (MOG.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Green Plains Inc (GPRE)：企業の財務・戦略的SWOT分析
    Green Plains Inc (GPRE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Lanka IOC PLC (LIOC.N0000)：企業の財務・戦略的SWOT分析
    Summary Lanka IOC Plc (LIOC), a subsidiary of Indian Oil Corporation Ltd is an oil and gas company that imports, sells and distributes petroleum products. The company's products include lubricants, fuels, bitumen and bunkering products. It provides automotive lubricants, including passenger car, die …
  • OmniGuide Inc：医療機器：M&Aディール及び事業提携情報
    Summary OmniGuide Inc (OmniGuide) is a medical device company that offers microsurgery, laparoscopy, and robotic assisted surgery products. The company’s products comprise GYN systems, ENT systems, OTO systems, line of sight systems, robotic surgical products and others. It also offers gynecology su …
  • Kimco Realty Corporation (KIM)：企業の財務・戦略的SWOT分析
    Kimco Realty Corporation (KIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Murphy Oil Corporation：戦略・SWOT・企業財務分析
    Murphy Oil Corporation - Strategy, SWOT and Corporate Finance Report Summary Murphy Oil Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Bracco SpA：企業の戦略的SWOT分析
    Bracco SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Allergan plc：企業のM&A・事業提携・投資動向
    Allergan plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Allergan plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Chong Kun Dang Pharmaceutical Corp (185750)：製薬・医療：M&Aディール及び事業提携情報
    Summary Chong Kun Dang Pharmaceutical Corp (CKD Pharma) manufactures, distributes, imports and exports prescription drugs, active pharmaceutical ingredients (APIs), over-the-counter (OTC) drugs, health supplements and consumer health products. Its product portfolio includes prescription products for …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆